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1. Introduction 
Affinity chromatography has recently been intro- 
duced as a method for purification of biologically ac- 
tive compounds [ 11. The method depends on the af- 
finity of a protein towards its specific hapten or in- 
hibitor covalently coupled to an insoluble matrix. In 
contrast to other chromatographic methods which 
separate proteins according to their size and charge, 
affinity chromatography separates proteins on the 
basis of their functional specificity and has been ap- 
plied to the isolation of enzymes [ 1, 21, antibodies 
[3], antigens [4, 51 and receptors [6]. 
Several laboratories have reported the purification 
of trypsin by using a protein inhibitor covalently at- 
tached to Sepharose [7,8] . We report here a new ap- 
proach for the isolation of trypsin as its soluble com- 
plex with dinitrophenylated soybean trypsin inhibi- 
tor (DNP-STI) on an antidinitrophenyl antibody col- 
umn [4,5] . The procedure involves the following 
steps: i) Dinitrophenylation of ST1 with dinitroben- 
zene sulfonate. ii) Formation of the complex between 
the DNP-ST1 and trypsin. iii) The complex is ad- 
sorbed to the anti-DNP-column and eluted from the 
column under conditions which dissociate antigen- 
antibody complexes. iv) Separation of the complex 
to its components to give pure trypsin. 
Although this paper describes the isolation of tryp- 
sin, the principles and techniques are clearly applica- 
ble to virtually all interacting systems comprised of 
two or more components, such as hormone-receptor 
interactions. 
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2. Materials and methods 
2.1. Materials 
Soybean-trypsin inhibitor, and trypsin were ob- 
tained from Worthington Biochemical Corp., 
Freehold, N.J. Sepharose 4B and Sephadox G-75 
were purchased from Pharmacia, Uppsala, Sweden. 
Dinitrobenzenesulfonate was a product of Fluka, 
A.G., Buchs, Switzerland. N-Benzoyl-L-arginine 
ethyl ester (BAEE) was a product of Miles-Yeda, 
Rehovot, Israel. 
2.2. Methods 
Goat anti-DNP antibodies were prepared from 
goat serum by affinity chromatography on DNP-oval- 
bumin-Sepharose column [3]. Coupling of antibodies 
to Sepharose was performed as previously described 
[4] . Amino acid analysis was performed essentially 
as described by Moore and Stein [9] using a one col- 
umn system. No corrections were made for the de- 
struction of amino acids during acid hydrolysis (6 M 
HCI 11 O”, 24 hr). Absorbance of proteins or their 
derivatives was read at appropriate wavelengths using 
an Acta V Beckman spectrophotometer. Tryptic ac- 
tivity was determined spectrophotometrically follow- 
ing the hydrolysis of BAEE at pH 8.0 [lo] , 
2.3. Dinitrophenylation of soybean trypsin inhibitor 
A solution of 24 mg ST1 in 1 ml of 1 M sodium bi- 
carbonate was reacted with 40 mg dinitrobenzenesul- 
fonate at 37” for 2 hr. The protein was then dialyzed 
against 0.02 M sodium acetate pH 5.0. The precipitate 
formed was dissolved in 0.1 M ammonium bicarbon- 
ate pH 8.4. The protein emerged as a single peak 
when chromatographed on Sephadex G-75. 
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Fig. 1. Fractionation of DNP-ST1 on anti-DNP-Sepharose col- 
umn. DNP-ST1 (10 mg) was applied to a 0.5 X 10 cm anti- 
DNP-Sepharose column. After washing with 0.1 M NH4HCOa 
the column was washed with water (A). The DNP-ST1 was 
eluted with 10% formic acid (B). Absorbance at 280 nm 
(o-o-o), absorbance at 335 nm (o-o-o). 
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Fig. 2. Gel filtration of dinitrophenylated STI-trypsin com- 
plex. A mixture of 18 mg of trypsin and 10 mg DNP-ST1 in 
1 ml of 0.05 M NHaHCOa, pH 8.4 was applied to column 
(1.5 X 90 cm) of Sephadex G-75 previously equilibrated with 
the same buffer. Column was eluted at a flow rate of 12 
ml/hr and monitored at 280 nm (*-o--a) and at 335 nm 
(o-o-o). Volume of fractions 5 ml/tube. 
ml 
Fig. 3. Isolation of DNP-STI-trypsin complex on anti-DNP- 
Sepharose. A mixture of 3 mg of DNP-ST1 and of 10 mg of 
trypsin in 1 ml of 0.1 M NH4HCOa was applied to 0.5 X 10 
column of anti-DNP-Sepharose. After washing with 0.1 M 
NH4HCOs and water (A) elution was started with 10% form- 
ic acid (B). Absorbance at 280 nm (e-o-o). Absorbance 
at 335 nm (o-o-o). 
3. Results 
The reaction of ST1 with dinitrobenzene sulfonate 
modified 2 to 4 lysines out of the eleven present in 
the protein [lo] . The separation of dinitrophenyl- 
ated ST1 (with at least one DNP group per mole of 
protein) from the protein that remained unmodified 
was accomplished by chromatography on anti-DNP- 
Sepharose column. All the DNP-ST1 was adsorbed, 
while native unmodified ST1 passed unretarded (fig. 
1). 
It was found that the DNP-ST1 still inhibits tryp- 
sin and 1 mg of DNP-ST1 binds 1.8 mg of trypsin. 
Passage of a solution of 10 mg DNP-ST1 and 18 mg of 
trypsin through a column of Sephadex G-75 permit- 
ted the isolation of the DNP-STI-trypsin complex. 
The yellow coloured complex which corresponds to 
the first peak (fig. 2) represented 92% of the protein 
applied to the column. 
Isolation of the complex by chromatography on 
Sephadex G-75 column as mentioned above is non- 
specific. It would not ensure the homogeneity of 
complex isolated when using biological material 
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Fig. 4. Absorption spectra of DNP-ST1 (---), and of DNP-STI-trypsin complex (-) isolated from the anti-DNP-antibody col- 
umn. 
containing trypsin without prior purification. Several 
other proteins, similar in size to the complex, could 
be expected as contaminants. Hence to isolate a pure 
complex, the solution containing the complex DNP- 
STI-trypsin was applied to the anti-DNP-Sepharose 
column. The amount of complex adsorbed was equiv- 
alent to the amount of bound antibody. Free trypsin 
or complex not containing dinitrophenyl groups was 
not adsorbed by the antibody column. Fig. 3 depicts 
the use of the anti-DNP-Sepharose columns for the 
isolation of the DNP-STI-trypsin complex. A mix- 
ture of DNPSTI(3 mg) and excess trypsin (10 mg) 
was passed through the column at room temp. Most 
of the yellow material was adsorbed to the column 
and could be eluted with 10% formic acid, or e-DNP- 
lysine. After treatment with formic acid the antibody 
Sepharose column was immediately washed with wa- 
ter and 0.1 M NH4HC03 and can be used again but 
with reduced capacity. The eluted yellow DNP-STI- 
trypsin complex (fig. 4) which did not possess any 
tryptic activity was lyophilized, dissolved in 0.1 M 
KC1 pH 2 and applied to the Sephadex G-75 column 
equilibrated with the same solvent. The first peak was 
collected and found to contain 55% of the original 
tryptic activity. 
4. Discussion 
In this study trypsin was used as a model com- 
pound in the development of a new approach for the 
purification of proteins present in minute amounts 
which possess the ability to complex with other com- 
pounds. 
The 4-step method described in this communica- 
tion takes advantage of the biological specificity of 
antibodies. It is based on the affinity of the antibody 
to a certain l&and attached to a complex of two or 
more proteins and is independent of the chemical, 
physical and biological properties of the complex it- 
self. Only the complexes which possess uch a ligand 
will be specifically sequestered by the antibodies and 
thereby removed from the entire extract of proteins. 
The introduction of Sepharose as a convenient sup. 
port for insolubilizing antibodies [4] allows the em- 
ployment of small columns for the isolation of micro- 
mole amounts of the complex. The antibody 
Sepharose column can also serve as a means for con- 
centrating the complex. Thus, the adsorbed complex 
can be recovered in approximately the volume of the 
antibody Sepharose column, regardless of the volume 
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in which the complex was applied to this column. The 
adsorption of the DNP-STI-trypsin complex was ac- 
complished under mild conditions. The elution of the 
complex from the antibody column required more 
drastic conditions such as 10% formic acid. The com- 
plex was also eluted with the hapten e-DNP-lysine 
but after this treatment the removal of the e-DNP-ly- 
sine from the column required 6 M guanidine hydro- 
chloride. The use of 6 M GnHCl causes substantial in- 
activation of the antibodies, and the column could 
not be used again efficiently. Since the elution of 
DNP hapten from the antibody column requires dras- 
tic conditions, attempts are now being made to modi- 
fy the proteins with other haptens such as arsanilic 
acid, which dissociate from the antibody column un- 
der mild conditions, e.g. 0.1 M acetic acid or 0.8 M 
NH40H. After such treatment the column can be 
regenerated to full capacity, and can be used many 
times. 
The use of antibodies as a tool for the isolation of 
complexed molecules can be extended to many other 
instances, since antibodies can be raised against al- 
most any hapten. Attempts to isolate specific pro- 
teins from membranes may be divided into two types: 
i) The protein is specifically labelled in situ, solubil- 
ized and then purified. The preparation of antibodies 
to the labeling molecule will provide means for the 
isolation of the labeled protein in one step. ii) In the 
other approach the membrane is solubilized, and the 
protein identified and purified. This approach was 
recently used for the isolation of insulin receptor of 
liver cell membranes on an insulin Sepharose column 
[6] . Studies are in progress in the use of anti-DNP- 
Sepharose columns for the isolation of the complex 
containing DNP-[1125] -insulin-specific receptor 
from human lymphocytes. 
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